推薦產品
生物源
mouse
品質等級
100
500
共軛
unconjugated
抗體表格
culture supernatant
抗體產品種類
primary antibodies
無性繁殖
124, monoclonal
描述
For In Vitro Diagnostic Use in Select Regions (See Chart)
形狀
buffered aqueous solution
物種活性
human
包裝
vial of 0.1 mL concentrate (226M-94)
vial of 0.5 mL concentrate (226M-95)
bottle of 1.0 mL predilute (226M-97)
vial of 1.0 mL concentrate (226M-96)
bottle of 7.0 mL predilute (226M-98)
製造商／商標名
Cell Marque™
技術
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
同型
IgG1κ
控制
tonsil
運輸包裝
wet ice
儲存溫度
2-8°C
視覺化
cytoplasmic
基因資訊
human ... BCL2(596)
一般說明
Anti-BCL2 has shown consistent negative reaction on reactive germinal centers and positive staining of neoplastic follicles in follicular lymphoma. Consequently, this antibody is valuable when distinguishing between reactive and neoplastic follicular proliferation in lymph node biopsies. This antibody may also be used in distinguishing between those follicular lymphomas that express BCL2 protein and the small number in which the neoplastic cells are BCL2 negative. Anti-BCL2 has been used as a predictive biomarker for recurrence in the case of radical prostatectomy for prostate cancer, and has shown promise as a prognostic marker in the case of cancer of the breast and non-small cell carcinoma of the lung.
品質
 IVD |  IVD |  IVD |  RUO |
聯結
BCL2 Positive Control Slides, Product No. 226S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
外觀
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
準備報告
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
其他說明
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法律資訊
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
未找到適合的產品？
試用我們的產品選擇工具.
從最近期的版本中選擇一個：
B Martin et al.
British journal of cancer, 89(1), 55-64 (2003-07-03)
The role of the anti-apoptotic protein Bcl-2 in lung cancer remains controversial. In order to clarify its impact on survival in small and non-small cell lung cancer (NSCLC), we performed a systematic review of the literature. Trials were selected for
J W Moul
European urology, 35(5-6), 399-407 (1999-05-15)
Within the past 5 years, research has increasingly addressed molecular alterations in prostate cancer (CaP). Mutations of tumor suppressor gene p53 have been found in a variety of cancers, including urologic neoplasms. Several studies have been conducted on CaP specimens
D R Ciocca et al.
Endocrine, 13(1), 1-10 (2000-10-29)
Tamoxifen is one of the most effective treatments for breast cancer. Standard practice is to select patients who are likely to respond to this therapy through the evaluation of estrogen receptor (ER) and progesterone receptor (PR) in the primary tumor
M L Cleary et al.
Cell, 47(1), 19-28 (1986-10-10)
cDNAs for the bcl-2 mRNA were cloned from a human common acute lymphoblastic leukemia cell line. Nucleotide sequence analyses showed that the 6 kb bcl-2 mRNA potentially encodes a 26 kd protein that is homologous to a predicted Epstein-Barr virus
D Hockenbery et al.
Nature, 348(6299), 334-336 (1990-11-22)
The t(14; 18) chromosomal translocation of human follicular B-cell lymphoma juxtaposes the bcl-2 gene with the immunoglobulin heavy chain locus. The bcl-2 immunoglobulin fusion gene is markedly deregulated resulting in inappropriately elevated levels of bcl-2 RNA and protein. Transgenic mice
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務